Monitor for upcoming KROS pipeline catalysts (clinical trial readouts) and any 8-K filings that might explain the coordinated officer selling. The C-suite cluster sell at identical prices on the same day is unusual for a pre-revenue biotech, watch for a potential equity offering or restructuring announcement. If the selling was tax-related, it is neutral; if it precedes negative clinical data, it is bearish. The director buy provides a modest counter-signal but is too small to override the officer cluster.
KROS drugs
KROS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 21 $11.03entry
- T+1 · 3mo ago −2.27%α −1.97% · $10.78
- T+5 · 3mo ago 0.00%α −0.47% · $11.03
- T+20 · 8w ago +4.08%α +3.06% · $11.48
- T+60 · 20h ago −9.07%α −5.70% · $10.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Keros Therapeutics insiders executed a mixed cluster: one director bought $10K worth of shares, while three C-suite officers and one director sold a combined $101K on the same day. The selling is concentrated among senior executives (CSO, CLO, VP Finance) at identical prices, suggesting coordinated liquidity or tax-related selling rather than a bearish signal, but the asymmetry between a small director buy and larger officer sells warrants attention. At $220M market cap, the $111K total is ~0.05% of market cap, trivial in magnitude, but the C-suite cluster sell pattern is notable given the company's pre-revenue biotech status and upcoming pipeline catalysts.
Key Financial Metrics
Key Facts
- Director Jean Jacques Bienaime bought 1,000 shares at $10.27 for $10,270 on 2026-08-17.
- CSO Lorena Lerner sold 3,568 shares at $10.29 for $36,715 on 2026-08-18.
- CLO Esther Cho sold 4,485 shares at $10.29 for $46,151 on 2026-08-18.
- VP Finance Annita Tanini sold 1,224 shares at $10.29 for $12,595 on 2026-08-18.
- Director Charles Newton sold 551 shares at $10.30 for $5,675 on 2026-08-18.
- Total cluster value of $111K represents ~0.05% of KROS's $220M market cap.
- Three C-suite officers sold on the same day at identical prices, suggesting a coordinated event (e.g., tax withholding, 10b5-1 plan, or blackout window opening).
- The single director buy is small and does not offset the officer sell cluster.
Financial Impact
Total insider trading of $111K, with $101K in sales and $10K in purchases, representing ~0.05% of market cap.
Risk Factors
- Coordinated C-suite selling may indicate upcoming negative clinical trial results or financing dilution.
- Pre-revenue biotech with $220M market cap is highly sensitive to pipeline data, insider selling ahead of catalysts is a red flag.
- The director buy is small ($10K) and may be a routine diversification or signaling gesture, not a conviction signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KROS-1787292502397 |
Track record
27 reports on KROS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers